Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 198

1.

Drug-Homogeneity Index in Mass-Spectrometry Imaging.

Prasad M, Postma G, Morosi L, Giordano S, Giavazzi R, D'Incalci M, Falcetta F, Davoli E, Jansen J, Franceschi P.

Anal Chem. 2018 Nov 8. doi: 10.1021/acs.analchem.8b01870. [Epub ahead of print]

PMID:
30359532
2.

Soluble stroma-related biomarkers of pancreatic cancer.

Resovi A, Bani MR, Porcu L, Anastasia A, Minoli L, Allavena P, Cappello P, Novelli F, Scarpa A, Morandi E, Falanga A, Torri V, Taraboletti G, Belotti D, Giavazzi R.

EMBO Mol Med. 2018 Aug;10(8). pii: e8741. doi: 10.15252/emmm.201708741.

3.

Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts.

Guffanti F, Fratelli M, Ganzinelli M, Bolis M, Ricci F, Bizzaro F, Chilà R, Sina FP, Fruscio R, Lupia M, Cavallaro U, Cappelletti MR, Generali D, Giavazzi R, Damia G.

Oncotarget. 2018 May 15;9(37):24707-24717. doi: 10.18632/oncotarget.25185. eCollection 2018 May 15.

4.

Tumor progression and metastatic dissemination in ovarian cancer after dose-dense or conventional paclitaxel and cisplatin plus bevacizumab.

Bizzaro F, Falcetta F, D'Agostini E, Decio A, Minoli L, Erba E, Alessandro Peccatori F, Scanziani E, Colombo N, Zucchetti M, Bani MR, Ubezio P, Giavazzi R.

Int J Cancer. 2018 Nov 1;143(9):2187-2199. doi: 10.1002/ijc.31596. Epub 2018 Aug 7.

PMID:
29752717
5.

Anti-angiogenesis for cancer: Current status and prospects.

Russo M, Giavazzi R.

Thromb Res. 2018 Apr;164 Suppl 1:S3-S6. doi: 10.1016/j.thromres.2018.01.030.

PMID:
29703482
6.

Modeling Cytostatic and Cytotoxic Responses to New Treatment Regimens for Ovarian Cancer.

Falcetta F, Bizzaro F, D'Agostini E, Bani MR, Giavazzi R, Ubezio P.

Cancer Res. 2017 Dec 1;77(23):6759-6769. doi: 10.1158/0008-5472.CAN-17-1099. Epub 2017 Sep 26.

PMID:
28951463
7.

Erratum to: Contribution of tumor endothelial cells to drug resistance: anti-angiogenic tyrosine kinase inhibitors act as p-glycoprotein antagonists.

Bani M, Decio A, Giavazzi R, Ghilardi C.

Angiogenesis. 2017 May;20(2):243-244. doi: 10.1007/s10456-017-9558-5. No abstract available.

PMID:
28488224
8.

Contribution of tumor endothelial cells to drug resistance: anti-angiogenic tyrosine kinase inhibitors act as p-glycoprotein antagonists.

Bani M, Decio A, Giavazzi R, Ghilardi C.

Angiogenesis. 2017 May;20(2):233-241. doi: 10.1007/s10456-017-9549-6. Epub 2017 Apr 7. Erratum in: Angiogenesis. 2017 May;20(2):243-244.

PMID:
28389777
9.

Heterogeneity of paclitaxel distribution in different tumor models assessed by MALDI mass spectrometry imaging.

Giordano S, Zucchetti M, Decio A, Cesca M, Fuso Nerini I, Maiezza M, Ferrari M, Licandro SA, Frapolli R, Giavazzi R, Maurizio D, Davoli E, Morosi L.

Sci Rep. 2016 Dec 21;6:39284. doi: 10.1038/srep39284.

10.

Orthotopic Model of Ovarian Cancer.

Decio A, Giavazzi R.

Methods Mol Biol. 2016;1464:139-149.

PMID:
27858363
11.

Correction: Sunitinib prevents cachexia and prolongs survival of mice bearing renal cancer by restraining STAT3 and MuRF-1 activation in muscle.

Pretto F, Ghilardi C, Moschetta M, Bassi A, Rovida A, Scarlato V, Talamini L, Fiordaliso F, Bisighini C, Damia G, Bani MR, Piccirillo R, Giavazzi R.

Oncotarget. 2016 Jun 21;7(25):38973. doi: 10.18632/oncotarget.9971. No abstract available.

12.

Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics.

Fuso Nerini I, Cesca M, Bizzaro F, Giavazzi R.

Chin J Cancer. 2016 Jun 29;35(1):61. doi: 10.1186/s40880-016-0123-1. Review.

13.

Activation of the SDF1/CXCR4 pathway retards muscle atrophy during cancer cachexia.

Martinelli GB, Olivari D, Re Cecconi AD, Talamini L, Ottoboni L, Lecker SH, Stretch C, Baracos VE, Bathe OF, Resovi A, Giavazzi R, Cervo L, Piccirillo R.

Oncogene. 2016 Dec 1;35(48):6212-6222. doi: 10.1038/onc.2016.153. Epub 2016 May 23.

PMID:
27212031
14.

PO-44 - Tissue factor pathway inhibitor-2 (TFPI-2) is cleaved by PRSS3: implication for tumor endothelial cells migration.

Ghilardi C, Anastasia A, Avigni R, Lupi M, Giavazzi R, Bani MR.

Thromb Res. 2016 Apr;140 Suppl 1:S192-3. doi: 10.1016/S0049-3848(16)30177-3. Epub 2016 Apr 8.

PMID:
27161730
15.

PO-15 - Antiangiogenic small molecule ligands of FGF2 derived from the endogenous inhibitor thrombospondin-1.

Pinessi D, Foglieni C, Bugatti A, Moroni E, Resovi A, Ribatti D, Rusnati M, Giavazzi R, Colombo G, Taraboletti G.

Thromb Res. 2016 Apr;140 Suppl 1:S182. doi: 10.1016/S0049-3848(16)30148-7. Epub 2016 Apr 8.

PMID:
27161705
16.

Bevacizumab-Induced Inhibition of Angiogenesis Promotes a More Homogeneous Intratumoral Distribution of Paclitaxel, Improving the Antitumor Response.

Cesca M, Morosi L, Berndt A, Fuso Nerini I, Frapolli R, Richter P, Decio A, Dirsch O, Micotti E, Giordano S, D'Incalci M, Davoli E, Zucchetti M, Giavazzi R.

Mol Cancer Ther. 2016 Jan;15(1):125-35. doi: 10.1158/1535-7163.MCT-15-0063. Epub 2015 Oct 22.

17.

Trypsinogen 4 boosts tumor endothelial cells migration through proteolysis of tissue factor pathway inhibitor-2.

Ghilardi C, Silini A, Figini S, Anastasia A, Lupi M, Fruscio R, Giavazzi R, Bani MR.

Oncotarget. 2015 Sep 29;6(29):28389-400. doi: 10.18632/oncotarget.4949.

18.

Cediranib combined with chemotherapy reduces tumor dissemination and prolongs the survival of mice bearing patient-derived ovarian cancer xenografts with different responsiveness to cisplatin.

Decio A, Cesca M, Bizzaro F, Porcu L, Bettolini R, Ubezio P, Taraboletti G, Belotti D, Giavazzi R.

Clin Exp Metastasis. 2015 Oct;32(7):647-58. doi: 10.1007/s10585-015-9734-1. Epub 2015 Jul 17.

PMID:
26185056
19.

Inactivating STAT3: bad for tumor, good for muscle.

Piccirillo R, Giavazzi R.

Cell Cycle. 2015;14(7):939-40. doi: 10.1080/15384101.2015.1010979. No abstract available.

20.

Sunitinib prevents cachexia and prolongs survival of mice bearing renal cancer by restraining STAT3 and MuRF-1 activation in muscle.

Pretto F, Ghilardi C, Moschetta M, Bassi A, Rovida A, Scarlato V, Talamini L, Fiordaliso F, Bisighini C, Damia G, Bani MR, Piccirillo R, Giavazzi R.

Oncotarget. 2015 Feb 20;6(5):3043-54. Erratum in: Oncotarget. 2016 Jun 21;7(25):38973.

21.

Patient-derived ovarian tumor xenografts recapitulate human clinicopathology and genetic alterations.

Ricci F, Bizzaro F, Cesca M, Guffanti F, Ganzinelli M, Decio A, Ghilardi C, Perego P, Fruscio R, Buda A, Milani R, Ostano P, Chiorino G, Bani MR, Damia G, Giavazzi R.

Cancer Res. 2014 Dec 1;74(23):6980-90. doi: 10.1158/0008-5472.CAN-14-0274. Epub 2014 Oct 10.

22.

Thrombospondin-1 is part of a Slug-independent motility and metastatic program in cutaneous melanoma, in association with VEGFR-1 and FGF-2.

Borsotti P, Ghilardi C, Ostano P, Silini A, Dossi R, Pinessi D, Foglieni C, Scatolini M, Lacal PM, Ferrari R, Moscatelli D, Sangalli F, D'Atri S, Giavazzi R, Bani MR, Chiorino G, Taraboletti G.

Pigment Cell Melanoma Res. 2015 Jan;28(1):73-81. doi: 10.1111/pcmr.12319. Epub 2014 Oct 13.

PMID:
25256553
23.

Antiangiogenic activity of trabectedin in myxoid liposarcoma: involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1.

Dossi R, Frapolli R, Di Giandomenico S, Paracchini L, Bozzi F, Brich S, Castiglioni V, Borsotti P, Belotti D, Uboldi S, Sanfilippo R, Erba E, Giavazzi R, Marchini S, Pilotti S, D'Incalci M, Taraboletti G.

Int J Cancer. 2015 Feb 1;136(3):721-9. doi: 10.1002/ijc.29023. Epub 2014 Jun 19.

24.

Intratumor heterogeneity and its impact on drug distribution and sensitivity.

Fuso Nerini I, Morosi L, Zucchetti M, Ballerini A, Giavazzi R, D'Incalci M.

Clin Pharmacol Ther. 2014 Aug;96(2):224-38. doi: 10.1038/clpt.2014.105. Epub 2014 May 14. Review.

PMID:
24827540
25.

Vascular endothelial growth factor c promotes ovarian carcinoma progression through paracrine and autocrine mechanisms.

Decio A, Taraboletti G, Patton V, Alzani R, Perego P, Fruscio R, Jürgensmeier JM, Giavazzi R, Belotti D.

Am J Pathol. 2014 Apr;184(4):1050-1061. doi: 10.1016/j.ajpath.2013.12.030. Epub 2014 Feb 6. Erratum in: Am J Pathol. 2014 Jul;184(7):2144.

PMID:
24508126
26.

Tumor delivery of chemotherapy combined with inhibitors of angiogenesis and vascular targeting agents.

Cesca M, Bizzaro F, Zucchetti M, Giavazzi R.

Front Oncol. 2013 Oct 1;3:259. doi: 10.3389/fonc.2013.00259. Review.

27.

Syngeneic murine metastasis models: B16 melanoma.

Giavazzi R, Decio A.

Methods Mol Biol. 2014;1070:131-40. doi: 10.1007/978-1-4614-8244-4_10.

PMID:
24092437
28.

Determination of paclitaxel distribution in solid tumors by nano-particle assisted laser desorption ionization mass spectrometry imaging.

Morosi L, Spinelli P, Zucchetti M, Pretto F, Carrà A, D'Incalci M, Giavazzi R, Davoli E.

PLoS One. 2013 Aug 26;8(8):e72532. doi: 10.1371/journal.pone.0072532. eCollection 2013.

29.

Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib.

Zucchetti M, Bonezzi K, Frapolli R, Sala F, Borsotti P, Zangarini M, Cvitkovic E, Noel K, Ubezio P, Giavazzi R, D'Incalci M, Taraboletti G.

Cancer Chemother Pharmacol. 2013 Oct;72(4):879-87. doi: 10.1007/s00280-013-2270-2. Epub 2013 Aug 24.

PMID:
23978989
30.

Chemotherapy counteracts metastatic dissemination induced by antiangiogenic treatment in mice.

Rovida A, Castiglioni V, Decio A, Scarlato V, Scanziani E, Giavazzi R, Cesca M.

Mol Cancer Ther. 2013 Oct;12(10):2237-47. doi: 10.1158/1535-7163.MCT-13-0244. Epub 2013 Aug 5. Erratum in: Mol Cancer Ther. 2014 Jan;13(1):270.

31.

The tyrosine kinase inhibitor E-3810 combined with paclitaxel inhibits the growth of advanced-stage triple-negative breast cancer xenografts.

Bello E, Taraboletti G, Colella G, Zucchetti M, Forestieri D, Licandro SA, Berndt A, Richter P, D'Incalci M, Cavalletti E, Giavazzi R, Camboni G, Damia G.

Mol Cancer Ther. 2013 Feb;12(2):131-40. doi: 10.1158/1535-7163.MCT-12-0275-T. Epub 2012 Dec 27.

32.

A complex of α6 integrin and E-cadherin drives liver metastasis of colorectal cancer cells through hepatic angiopoietin-like 6.

Marchiò S, Soster M, Cardaci S, Muratore A, Bartolini A, Barone V, Ribero D, Monti M, Bovino P, Sun J, Giavazzi R, Asioli S, Cassoni P, Capussotti L, Pucci P, Bugatti A, Rusnati M, Pasqualini R, Arap W, Bussolino F.

EMBO Mol Med. 2012 Nov;4(11):1156-75. doi: 10.1002/emmm.201101164. Epub 2012 Oct 16.

33.

Inhibition of SIRT2 potentiates the anti-motility activity of taxanes: implications for antineoplastic combination therapies.

Bonezzi K, Belotti D, North BJ, Ghilardi C, Borsotti P, Resovi A, Ubezio P, Riva A, Giavazzi R, Verdin E, Taraboletti G.

Neoplasia. 2012 Sep;14(9):846-54.

34.

Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models.

Oliva P, Decio A, Castiglioni V, Bassi A, Pesenti E, Cesca M, Scanziani E, Belotti D, Giavazzi R.

Br J Cancer. 2012 Jul 10;107(2):360-9. doi: 10.1038/bjc.2012.261. Epub 2012 Jun 19.

35.

Paclitaxel enhances therapeutic efficacy of the F8-IL2 immunocytokine to EDA-fibronectin-positive metastatic human melanoma xenografts.

Moschetta M, Pretto F, Berndt A, Galler K, Richter P, Bassi A, Oliva P, Micotti E, Valbusa G, Schwager K, Kaspar M, Trachsel E, Kosmehl H, Bani MR, Neri D, Giavazzi R.

Cancer Res. 2012 Apr 1;72(7):1814-24. doi: 10.1158/0008-5472.CAN-11-1919. Epub 2012 Mar 5.

36.

Regulator of G-protein signaling 5 (RGS5) protein: a novel marker of cancer vasculature elicited and sustained by the tumor's proangiogenic microenvironment.

Silini A, Ghilardi C, Figini S, Sangalli F, Fruscio R, Dahse R, Pedley RB, Giavazzi R, Bani M.

Cell Mol Life Sci. 2012 Apr;69(7):1167-78. doi: 10.1007/s00018-011-0862-8. Epub 2011 Dec 1.

37.

Differential vascular expression and regulation of oncofetal tenascin-C and fibronectin variants in renal cell carcinoma (RCC): implications for an individualized angiogenesis-related targeted drug delivery.

Galler K, Junker K, Franz M, Hentschel J, Richter P, Gajda M, Göhlert A, von Eggeling F, Heller R, Giavazzi R, Neri D, Kosmehl H, Wunderlich H, Berndt A.

Histochem Cell Biol. 2012 Feb;137(2):195-204. doi: 10.1007/s00418-011-0886-z. Epub 2011 Nov 11.

PMID:
22075565
38.

Targeting angiogenesis with compounds from the extracellular matrix.

Belotti D, Foglieni C, Resovi A, Giavazzi R, Taraboletti G.

Int J Biochem Cell Biol. 2011 Dec;43(12):1674-85. doi: 10.1016/j.biocel.2011.08.012. Epub 2011 Aug 17. Review.

PMID:
21864705
39.

Identification of thrombin-like activity in ovarian cancer associated ascites and modulation of multiple cytokine networks.

Naldini A, Morena E, Belotti D, Carraro F, Allavena P, Giavazzi R.

Thromb Haemost. 2011 Oct;106(4):705-11. doi: 10.1160/TH11-05-0311. Epub 2011 Aug 11.

PMID:
21833453
40.

The adhesion molecule NCAM promotes ovarian cancer progression via FGFR signalling.

Zecchini S, Bombardelli L, Decio A, Bianchi M, Mazzarol G, Sanguineti F, Aletti G, Maddaluno L, Berezin V, Bock E, Casadio C, Viale G, Colombo N, Giavazzi R, Cavallaro U.

EMBO Mol Med. 2011 Aug;3(8):480-94. doi: 10.1002/emmm.201100152. Epub 2011 Jul 8.

41.

E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models.

Bello E, Colella G, Scarlato V, Oliva P, Berndt A, Valbusa G, Serra SC, D'Incalci M, Cavalletti E, Giavazzi R, Damia G, Camboni G.

Cancer Res. 2011 Feb 15;71(4):1396-405. doi: 10.1158/0008-5472.CAN-10-2700. Epub 2011 Jan 6.

42.

Expression of the soluble vascular endothelial growth factor receptor-1 in cutaneous melanoma: role in tumour progression.

Ruffini F, Failla CM, Orecchia A, Bani MR, Dorio AS, Fortes C, Zambruno G, Graziani G, Giavazzi R, D'Atri S, Lacal PM.

Br J Dermatol. 2011 May;164(5):1061-70. doi: 10.1111/j.1365-2133.2010.10200.x.

PMID:
21198538
43.

Angiogenesis inhibitors: implications for combination with conventional therapies.

Moschetta M, Cesca M, Pretto F, Giavazzi R.

Curr Pharm Des. 2010;16(35):3921-31. Review.

PMID:
21158726
44.

The immunocytokine F8-IL2 improves the therapeutic performance of sunitinib in a mouse model of renal cell carcinoma.

Frey K, Schliemann C, Schwager K, Giavazzi R, Johannsen M, Neri D.

J Urol. 2010 Dec;184(6):2540-8. doi: 10.1016/j.juro.2010.07.030. Epub 2010 Oct 28.

PMID:
21030045
45.

Interleukin-1β regulates the migratory potential of MDAMB231 breast cancer cells through the hypoxia-inducible factor-1α.

Naldini A, Filippi I, Miglietta D, Moschetta M, Giavazzi R, Carraro F.

Eur J Cancer. 2010 Dec;46(18):3400-8. doi: 10.1016/j.ejca.2010.07.044. Epub 2010 Aug 26.

PMID:
20801015
46.

Dual targeting of tumor and endothelial cells by gonadotropin-releasing hormone agonists to reduce melanoma angiogenesis.

Moretti RM, Mai S, Montagnani Marelli M, Bani MR, Ghilardi C, Giavazzi R, Taylor DM, Martini PG, Limonta P.

Endocrinology. 2010 Oct;151(10):4643-53. doi: 10.1210/en.2010-0163. Epub 2010 Aug 4.

47.

A comparative analysis of oncofetal fibronectin and tenascin-C incorporation in tumour vessels using human recombinant SIP format antibodies.

Berndt A, Köllner R, Richter P, Franz M, Voigt A, Berndt A, Borsi L, Giavazzi R, Neri D, Kosmehl H.

Histochem Cell Biol. 2010 Apr;133(4):467-75. doi: 10.1007/s00418-010-0685-y. Epub 2010 Mar 17.

PMID:
20237793
48.

Protease-activated receptor-1 (PAR-1) promotes the motility of human melanomas and is associated to their metastatic phenotype.

Silini A, Ghilardi C, Ardinghi C, Bernasconi S, Oliva P, Carraro F, Naldini A, Bani MR, Giavazzi R.

Clin Exp Metastasis. 2010;27(1):43-53. doi: 10.1007/s10585-009-9301-8. Epub 2009 Dec 20.

PMID:
20084489
49.

Non-peptidic thrombospondin-1 mimics as fibroblast growth factor-2 inhibitors: an integrated strategy for the development of new antiangiogenic compounds.

Colombo G, Margosio B, Ragona L, Neves M, Bonifacio S, Annis DS, Stravalaci M, Tomaselli S, Giavazzi R, Rusnati M, Presta M, Zetta L, Mosher DF, Ribatti D, Gobbi M, Taraboletti G.

J Biol Chem. 2010 Mar 19;285(12):8733-42. doi: 10.1074/jbc.M109.085605. Epub 2010 Jan 7.

50.

A proteomic approach for the identification of vascular markers of liver metastasis.

Borgia B, Roesli C, Fugmann T, Schliemann C, Cesca M, Neri D, Giavazzi R.

Cancer Res. 2010 Jan 1;70(1):309-18. doi: 10.1158/0008-5472.CAN-09-2939. Epub 2009 Dec 8.

Supplemental Content

Loading ...
Support Center